Correction: Risk of thromboembolism in cisplatin versus carboplatin-treated patients with lung cancer.

Correction: Risk of thromboembolism in cisplatin versus carboplatin-treated patients with lung cancer.

[This corrects the article DOI: 10.1371/journal.pone.0189410.].

Bibliographic Details
Main Author:	PLOS Staff
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2018-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC5766248?pdf=render

Similar Items

Risk of thromboembolism in cisplatin versus carboplatin-treated patients with lung cancer.
by: Eric S Kim, et al.
Published: (2017-01-01)

Amrubicin: potential in combination with cisplatin or carboplatin to treat small-cell lung cancer
by: Ding Q, et al.
Published: (2013-08-01)

Real-world comparison of survival outcomes with cisplatin versus carboplatin in patients with limited-stage small-cell lung cancer
by: Shashank Sama, et al.
Published: (2023-01-01)

Carboplatin versus cisplatin in combination with etoposide in the first-line treatment of small cell lung cancer: a pooled analysis
by: Shiyu Jiang, et al.
Published: (2021-12-01)

Cisplatin or carboplatin in the treatment of non-small cell lung cancer: a comprehensive review
by: Marcello Tiseo, et al.
Published: (2011-12-01)

Cisplatin or carboplatin in the treatment of non-small cell lung cancer: a comprehensive review
by: Marcello Tiseo, et al.
Published: (2011-12-01)

Hypersensitivity and cross-reactivity to cisplatin and carboplatin
by: Gholamreza Faridaalaee, et al.
Published: (2016-07-01)

Paclitaxel-etoposide-carboplatin/cisplatin versus etoposidecarboplatin/cisplatin as first-line treatment for combined small-cell lung cancer: a retrospective analysis of 62 cases
by: Yue-Ya Li, et al.
Published: (2015-06-01)

Correction: Association of GWAS-identified lung cancer susceptibility loci with survival length in patients with small-cell lung cancer treated with platinum-based chemotherapy.
by: PLOS ONE Staff
Published: (2015-01-01)

Cisplatin, cyclophosphamide versus taxol, carboplatin in epithelial ovarian carcinoma: a clinical trial
by: Modarres M, et al.
Published: (2007-05-01)

Safety and Efficacy of Weekly Paclitaxel and Cisplatin Chemotherapy for Ovarian Cancer Patients with Hypersensitivity to Carboplatin
by: Shinichi Tate, et al.
Published: (2021-02-01)

Comparison of survival and adverse effect profile in patients with esophageal cancer treated with the combination of carboplatin and paclitaxel vs. 5-flourouracil and cisplatin
by: N. Nisar, et al.
Published: (2022-09-01)

Multi-institutional survey of antiemetic therapy in lung cancer patients treated with carboplatin in Hokushin region
by: Takayuki Ide, et al.
Published: (2023-06-01)

Concurrent chemoradiation with carboplatin for locally advanced cervical cancer at high-risk for developing cisplatin-induced renal dysfunction
by: Dueñas-Gonzalez Alfonso, et al.
Published: (2007-02-01)

Correction to: Safety and efficacy of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in neoadjuvant chemoradiotherapy for patients with locally advanced esophageal carcinoma: a retrospective study
by: Li Jiang, et al.
Published: (2023-05-01)

Synchronous lung and gastric cancers successfully treated with carboplatin and pemetrexed: a case report
by: Sato Takashi, et al.
Published: (2012-08-01)

A Potentially Less Nephrotoxicity of Carboplatin Over Cisplatin as Radiosensitizer in Head-neck Cancer
by: Mahfujul Ahmed Riad
Published: (2022-08-01)

Combination of gemcitabine and carboplatin in urothelial cancer patients unfit for cisplatin due to impaired renal or cardiac function
by: Avishay Sella, et al.
Published: (2012-02-01)

Comparison of Ifosfamide, Carboplatin and Etoposide versus Etoposide, Steroid, and Cytarabine Cisplatin as Salvage Chemotherapy in Patients with Refractory or Relapsed Hodgkin's lymphoma
by: Valiollah Mehrzad, et al.
Published: (2017-01-01)

Comparison of paclitaxel liposomes combined with carboplatin versus paclitaxel combined with carboplatin in the treatment of advanced ovarian cancer
by: Xiangbin Tan, et al.
Published: (2023-09-01)

Correction: A Newfound Association between MDC1 Functional Polymorphism and Lung Cancer Risk in Chinese.
by: PLOS ONE Staff
Published: (2015-01-01)

Pemetrexed Combined with Cisplatin or Carboplatin Regimen in the Treatment of Advanced Recurrent or Metastasis Non-small Cell Lung Cancer: Analysis of 63 Cases
by: Wei WANG, et al.
Published: (2011-01-01)

The influence of acute kidney disease on the clinical outcomes of patients who received cisplatin, carboplatin, and oxaliplatin
by: Alexandre Ricardo Da Silva Fernandes, et al.
Published: (2022-01-01)

Comparison of Neoadjuvant Chemotherapy Efficiency in Advanced Ovarian Cancer Patients Treated With Paclitaxel Plus Carboplatin and Intraperitoneal Bevacizumab vs. Paclitaxel With Carboplatin
by: Yin Tao, et al.
Published: (2022-03-01)

A Prospective Study of Adjuvant Radiotherapy Concomitant with Cisplatin Followed by Paclitaxel-Carboplatin in High Risk Early Stage Endometrial Cancer
by: Tarek Kamel, et al.
Published: (2016-12-01)

Chemoradiation with Cisplatin vs. Carboplatin for Squamous Cell Carcinoma of the Head and Neck (SCCHN)
by: Dirk Rades, et al.
Published: (2023-06-01)

Comparison of full-dose gemcitabine/cisplatin, dose-reduced gemcitabine/cisplatin, and gemcitabine/carboplatin in real-world patients with advanced urothelial carcinoma
by: Kazuma Sugimoto, et al.
Published: (2022-11-01)

Cisplatin and carboplatin result in similar gonadotoxicity in immature human testis with implications for fertility preservation in childhood cancer
by: Tharmalingam, MD, et al.
Published: (2020)

Correction: Evaluation of the Lung Cancer Risks at Which to Screen Ever- and Never-Smokers: Screening Rules Applied to the PLCO and NLST Cohorts.
by: PLOS Medicine Staff
Published: (2015-01-01)

Nomogram prediction for the risk of venous thromboembolism in patients with lung cancer
by: Haike Lei, et al.
Published: (2023-03-01)

Comparison of neoadjuvant chemoradiation with carboplatin/ paclitaxel or cisplatin/ 5-fluoruracil in patients with squamous cell carcinoma of the esophagus
by: Stefan Münch, et al.
Published: (2017-11-01)

Advanced non-small cell lung cancer in elderly patients: The standard every 3-weeks versus weekly paclitaxel with carboplatin
by: Hala Mohamed El-Shenshawy, et al.
Published: (2012-10-01)

Syndrome of Inappropriate Secretion of Antidiuretic Hormone Caused by Carboplatin After Switching from Cisplatin in a Metastatic Urethral Cancer Patient
by: Yosuke Sugiyama, et al.
Published: (2017-05-01)

Expression of drug targets in patients treated with sorafenib, carboplatin and paclitaxel.
by: Lucia B Jilaveanu, et al.
Published: (2013-01-01)

Irinotecan/cisplatin versus Etoposide/cisplatin for Patients with Extensive Stage Small Cell Lung Cancer: A Systematic Review
by: Nan YAO, et al.
Published: (2009-08-01)

Correction: Quantification of the Blood Platelet Reactivity in the ADP-Induced Model of Non-Lethal Pulmonary Thromboembolism in Mice with the Use of Laser Doppler Flowmetry.
by: PLOS ONE Staff
Published: (2016-01-01)

Safety and efficacy of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in neoadjuvant chemoradiotherapy for patients with locally advanced esophageal carcinoma: a retrospective study
by: Li Jiang, et al.
Published: (2022-12-01)

Survival and Side Effects of Cisplatin/Cyclophosphamide and Carboplatin/Paclitaxel Adjuvant Chemotherapy in Stage IC-IV Ovarian Cancer
by: Unedo H Markus, et al.
Published: (2015-04-01)

Correction: Risk of cancer in patients with iron deficiency anemia: a nationwide population-based study.
by: PLOS ONE Staff
Published: (2015-01-01)

Thromboembolic events in cancer patients on active treatment with cisplatin-based chemotherapy: another look!
by: Hikmat Abdel-Razeq, et al.
Published: (2018-03-01)